AI Article Synopsis
- This study investigates the effects of double-filtration plasmapheresis (DFPP) on clotting factors in kidney transplant recipients with antibody-mediated rejection (AMR) due to donor-specific antibodies (DSAs).
- Six patients underwent two cycles of DFPP followed by rituximab injections, and their fibrinogen and factor XIII (FXIII) levels were monitored.
- Results showed significant decreases in both fibrinogen and FXIII levels after each DFPP session, leading to the creation of a predictive model that could help doctors manage these clotting factors more effectively.
Article Abstract
Background/aims: Antibody-mediated rejection (AMR) is related to circulating donor-specific anti-human leukocyte antigen alloantibodies (DSAs). DSAs can be removed by apheresis, for example, double-filtration plasmapheresis (DFPP). However, DFPP removes some clotting factors (fibrinogen and factor XIII [FXIII]).
Methods: This was a prospective trial including 6 DSA-mediated AMR kidney transplant recipients. Patients received 2 cycles of 3-4 consecutive DFPP sessions followed by 1 injection of rituximab (break of 4-5 days between the 2 cycles). We monitored fibrinogen and FXIII levels before and after each session of DFPP.
Results: Overall, fibrinogen and FXIII levels were significantly decreased after each session, and were significantly reduced between the very first and very last sessions. In addition, we established a model that predicted fibrinogen and FXIII values after each session and after 2 cycles.
Conclusion: We established a model in order to predict fibrinogen and FXIII depletion after DFPP sessions; it may help clinicians supplement fibrinogen and/or FXIII when appropriate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000488928 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!